6
Participants
Start Date
April 30, 2015
Primary Completion Date
September 30, 2016
Study Completion Date
September 30, 2016
Administration of the malaria inoculum
Each participant in the cohort will be inoculated on Day 0 with \~2,800 viable parasites of Plasmodium falciparum-infected human erythrocytes (BSPC) administered intravenously. The threshold for commencement of treatment will be when PCR quantification of all participants is ≥ 5,000 parasites/mL.
Piperaquine Phosphate 480 mg
When PCR quantification of all participants is ≥ 5,000 parasites/mL, participants will receive a single dose of 480 mg Piperaquine Phosphate
Q-Pharm Clinics, Herston
Collaborators (1)
Q-Pharm Pty Limited
INDUSTRY
Clinical Network Services (CNS) Pty Ltd
INDUSTRY
Sullivan Nicolaides Pathology
INDUSTRY
QIMR Berghofer Medical Research Institute
OTHER
Army Malaria Institute, Australia
OTHER
Medicines for Malaria Venture
OTHER